Deferasirox
Contents
Description
Deferasirox is an oral iron chelator that binds to iron and promotes its excretion primarily through feces. It is indicated for chronic iron overload due to blood transfusions in patients with beta-thalassemia syndromes including hemoglobin E-beta-thalassemia. The drug selectively chelates iron with high affinity in a 2:1 ratio.
Indications & Therapeutic Use
chronic iron overload, transfusion-dependent thalassemia, hemoglobin E-beta-thalassemia syndrome, non-transfusion-dependent thalassemia
Linked Diseases:
Global Availability (10 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Deferasirox — GNH India
271 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
| Generic Name | deferasirox |
| Brands | 1 brand available |
| Active Ingredient | deferasirox |
| Drug Class | chronic iron overload |
| Manufacturer | Novartis |
| Dosage Forms | oral tablet, 125 mg, 250 mg, 500 mg; oral granules for suspension |
| Medical Code | V03AC03 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 5 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT00171821 |
| Countries | 10 countries |